Advances in Combination Therapies Based on Nanoparticles for Efficacious Cancer Treatment: An Analytical Report
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The main objective of nanomedicine research is the development of nanoparticles as drug delivery systems or drugs per se to tackle diseases as cancer, which are a leading cause of death with developed nations. Targeted treatments against solid tumors generally lead to dramatic regressions, but, unfortunately, the responses are often short-lived due to resistant cancer cells. In addition, one of the major challenges of combination drug therapy (called "cocktail") is the crucial optimization of different drug parameters. This issue can be solved using combination nanotherapy. Nanoparticles developed in oncology based on combination nanotherapy are either (a) those designed to combat multidrug resistance or (b) those used to circumvent resistance to clinical cancer drugs. This review provides an overview of the different nanoparticles currently used in clinical treatments in oncology. We analyze in detail the development of combinatorial nanoparticles including dendrimers for dual drug delivery via two strategic approaches: (a) use of chemotherapeutics and chemosensitizers to combat multidrug resistance and (b) use of multiple cytotoxic drugs. Finally, in this review, we discuss the challenges, clinical outlook, and perspectives of the nanoparticle-based combination therapy in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Applications of Nanoparticles in Biology
De, M., Ghosh, P. S., & Rotello, V. M. (2008) · Advanced Materials · doi:10.1002/adma.200703183 · Cited by 1,547
Nanoparticles as drug delivery systems
Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70901-5 · Cited by 1,445
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088
Kobayashi, H., Watanabe, R., & Choyke, P. L. (2014) · Theranostics · doi:10.7150/thno.7193 · Cited by 996
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Cited by
Polymeric Nanostructures for Imaging and Therapy
Elsabahy, M., Heo, G. S., Lim, S.-M., Sun, G., & Wooley, K. L. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00135 · Cited by 508
Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer
Gurunathan, S., Kang, M.-H., Qasim, M., & Kim, J.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103264 · Cited by 367
“Among several new therapeutic approaches, nanotechnology in cancer plays several roles including the detection and treatment of cancer, identification of biomarkers, understanding of cancer progress and guiding the development of new diagnostics and imaging agents [6].”
BackgroundDendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications
Santos, A., Veiga, F., & Figueiras, A. (2019) · Materials · doi:10.3390/ma13010065 · Cited by 313
“Additionally, they can reduce the therapeutic dosage by increasing the drug time of exposure, minimizing adverse drug side effects [21].”
BackgroundCheng, Y., Huang, F., Min, X., Gao, P., Zhang, T., Li, X., Liu, B., Hong, Y., Lou, X., & Xia, F. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02833 · Cited by 94
Yang, Y., Meng, Y., Ye, J., Xia, X., Wang, H., Li, L., Dong, W., Jin, D., & Liu, Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.028 · Cited by 49
Metadata
- Authors
- Mignani, S., Bryszewska, M., Klajnert-Maculewicz, B., Zablocka, M., & Majoral, J.-P.
- Venue
- Biomacromolecules
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-12-11
- Volume
- 16
- Issue
- 1
- Pages
- 1-27
- ISSN
- 1525-7797 (ISSN-L)
- 1526-4602
- OpenAlex
- W2317470873
- Cited by
- 139
- References
- 17
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.